| Literature DB >> 16458505 |
John F Miller1, C Webster Andrews, Michael Brieger, Eric S Furfine, Michael R Hale, Mary H Hanlon, Richard J Hazen, Istvan Kaldor, Ed W McLean, David Reynolds, Douglas M Sammond, Andrew Spaltenstein, Roger Tung, Elizabeth M Turner, Robert X Xu, Ronald G Sherrill.
Abstract
A novel series of P1 modified HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and protease inhibitor-resistant viruses. Optimization of the P1 moiety resulted in compounds with femtomolar enzyme activities and cellular antiviral activities in the low nanomolar range culminating in the identification of clinical candidate GW0385.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16458505 DOI： 10.1016/j.bmcl.2006.01.035
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823